Skip to main content
. Author manuscript; available in PMC: 2014 Aug 26.
Published in final edited form as: Nat Biotechnol. 2012 Mar 25;30(5):453–459. doi: 10.1038/nbt.2158

Figure 4. Bdnf-AS regulates Bdnf mRNA and protein in vivo.

Figure 4

(A–C) Using osmotic mini-pumps, we infused mBdnf-AntagoNAT9 (CAACATATCAGGAGCC) or control oligonucleotide (CCACGCGCAGTACATG) constantly over a period of 28 d, into the third ventricle of mouse brain (n=5 per treatment group *= P < 0.05, **= P < 0.01, ***= P < 0.001). mBdnf-AntagoNAT9 directed against Bdnf-AS but not the control oligonucleotide resulted in an increase in Bdnf levels in the hippocampus (A) and frontal cortex (B). In the hypothalamus (C) both transcripts were unchanged, as was expected for a tissue that is not directly connected to the third ventricle of the brain.

(D–E) We assessed BDNF protein levels by ELISA and found that mBdnf-AntagoNAT9 treatment results in an increase in BDNF protein, both in the hippocampus (D) and frontal cortex (E), as compared to control oligonucleotide treated mice.